SEC Tracker
Get the app

PAVmed PAVM

PAVmed FY 2021: revenue $500K

Form
10-K
Filed
Period
Importance
Notable
Document
10-K

Key figures from this report

These are the numbers PAVmed reported for the year ended Dec 31, 2021, as tagged in the filing’s XBRL data, each against the year before. A plain-English reading of this report is not written yet.

  1. Revenue$500KNo year-earlier figure tagged10-K income statement, on EDGAR
  2. Net income−$50.3MAgainst −$34.3M in FY 202010-K income statement, on EDGAR
  3. Cash and cash equivalents$77.3M+348% from $17.3M in FY 202010-K balance sheet, on EDGAR
  4. Cash from operations−$40.6MAgainst −$21.9M in FY 202010-K cash flow statement, on EDGAR

Every year in the financial tables

View on EDGAR

Open in the app

Get an email when PAVmed files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Same SIC code (3841) and public float under $300M, nearest public float first, as each company reports it on its annual report cover.

  1. Intelligent Bio Solutions INBS public float $12M, Dec 31, 2025
  2. PetVivo Holdings PETV public float $12M, Jun 29, 2026
  3. Lyra Therapeutics LYRA public float $11M, Jun 30, 2025
  4. Nexgel NXGL public float $11M, Jun 30, 2025
  5. Mountain Crest Acquisition Corp. V MCAG public float $10M, Jun 30, 2025